GlassScriptPhysician profile
Lalit P Patel
NPI 1770530065
$4,901.41
in general payments reported to CMS, 2019-2025
36 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $331 · 2021: $800 · 2022: $597 · 2023: $853 · 2024: $635 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Education: $7.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.84 |
| Education | $7.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $640.07 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $611.75 | 2019-2025 | Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $318.32 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.20 | 2023 | |
| Amarin Pharma, INC. | $288.64 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $232.65 | 2020-2025 | Seglentis, Livalo, Zoryve |
| Astellas Pharma US INC | $229.37 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $209.14 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.97 | 2019-2022 | |
| Abbvie INC. | $189.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.78 | 2022-2024 | Trulance, Xifaxan |
| Pfizer INC. | $175.23 | 2019-2024 | |
| Exact Sciences Corporation | $147.51 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $141.87 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $133.72 | 2019-2025 | Mounjaro, Zepbound |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.83 | 2021-2024 | Otezla, Repatha |
| Vifor Pharma, INC. | $91.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.01 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.21 | 2023 | Rexulti |
| Allergan, INC. | $53.40 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $50.24 | 2019 | |
| Shield Therapeutics INC | $47.57 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $46.88 | 2022 | |
| Xeris Pharmaceuticals, INC. | $41.80 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $38.75 | 2019 | |
| Merck Sharp & Dohme LLC | $36.43 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.44 | 2024 | Trelegy Ellipta |
| Becton, Dickinson and Company | $32.09 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.06 | 2022 | |
| Althera Pharmaceuticals LLC | $21.52 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $21.38 | 2023 | Inpefa |
| Redhill Biopharma INC. | $19.10 | 2022 | |
| Biogen, INC. | $18.66 | 2021 | |
| Hikma Pharmaceuticals USA | $18.18 | 2020 | |
| Horizon Therapeutics Plc | $17.66 | 2022 | |
| Virtus Pharmaceuticals LLC | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.